aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

aTyr Pharma, Inc.NASDAQ: ATYR

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$10.4M, compared with -$14.5M a year earlier. Trailing-twelve-month EBITDA was -$68.69M.

Context

  • EBITDA amounted to 38192.1% of revenue in FY2025, up 11604.0 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$39.42M (+45.7%) for the fiscal year ending Dec 2026, a step up from the -16.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.4M+23.4% QoQ
Last fiscal yearDec 2025
-$72.57M-16.1% YoY
LTMMar 2026
-$68.69M-10.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.3%——
1 year-16.1%+45.7%+61.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(72.57M) USD
Year-over-year change
-16.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.6% is the 5th highest of 8, against a peer median of -1.2%.
  • EBITDA amounts to 36154.2% of revenue for ATYR, versus a peer median of 89.7%.
ATYR Competitors
EBITDA for ATYR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HYFTMindWalk Holdings Corp.LTM Jan 2026-CA$10.88M CAD+76.6%—59.3%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$39.25M USD-164.0%——
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M USD-143.9%—89.7%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-$52.24M USD-1.2%—1327.8%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026-$58.88M USD-297.6%——
ATYRaTyr Pharma, Inc.LTM Mar 2026-$68.69M USD-10.6%—36154.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$82.08M USD+0.7%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$86.7M USD+32.0%——
Peer median (excluding ATYR) —-1.2%—89.7%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.